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ABSTRACT 
Background/Aim: Baveno VI and expanded Baveno VI non-invasive criteria can avoid the need for 
esophagogastroduodenoscopy(EGD) to screen for varices needing treatment(VNT) in a substantial proportion of compensated 
patients with viral and/or alcoholic cirrhosis. This multicenter, cross-sectional study aims to validate these criteria in patients with 
compensated cirrhosis due to nonalcoholic fatty liver disease(NAFLD), accounting for possible differences in liver stiffness 
measurement(LSM) values between M and XL probes.  
Materials/Methods:We assessed 790 patients with NAFLD-related compensated cirrhosis who had EGD within 6 months of a reliable 
LSM measured by FibroScan using M and/or XL probe. Baveno VI and expanded Baveno VI criteria were tested. The main variable 
used to optimize criteria was the percentage of endoscopies spared, keeping the risk of missing large VNT below a <5% threshold. 
Results: 314 patients had LSM by both M and XL probes(training set), while 338 and 138 by only M or XL probe, 
respectively(validation sets). In the training set use of Baveno VI and expanded Baveno VI criteria reduced by 33.3% and by 58% the 
number of EGD, missing 0.9% and 3.8% of large OV, respectively.  The best thresholds to rule-out VNT were identified at 
PLT>110,000 and LSM<30 KPa for M probe, and PLT>110,000 and LSM<25 KPa for XL probe(NAFLD cirrhosis criteria). These 
criteria spared 68.5% and 65% of EGD, by missing 4.2% and 4.9% of VNT, respectively. Usage of NAFLD cirrhosis criteria would have 
thus led to an absolute reduction in the number of EGD screened patients of 34.7% and 10.5% with respect to BAVENO VI and 
expanded BAVENO VI criteria respectively 
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Conclusion:The new NAFLD cirrhosis criteria, established for the FibroScan probe, can reduce by more than half the use of EGD to 
screen for VNT in NAFLD cirrhosis, with a chance of missing VNT below 5%. 
Keywords: Varices, NAFLD, Cirrhosis, Baveno, stiffness 
Introduction 
The pandemic spreading of obesity and diabetes makes nonalcoholic fatty liver disease (NAFLD) the growing most common cause of 
chronic liver disease and cirrhosis [1], an increasing risk factor for hepatocellular carcinoma [2], and the emerging indication for liver 
transplantation [3]. Consistent with these data the management of patients with NAFLD-related cirrhosis represents a challenge in 
terms of epidemiological, clinical and economical burden. In this complex picture, the diagnosis of esophageal varices (EV) and 
especially large (grade 2/3) EV requiring primary prophylaxis (varices needing treatment, VNT), is of paramount prognostic importance 
in all patients with cirrhosis including those with NAFLD [4,5]. However, VNT are not frequent in patients with compensated cirrhosis, 
and strategies to reduce the number of unnecessary esophagogastroduodenoscopy (EGD) screening have been proposed. Recently, 
the Baveno VI guidelines proposed that compensated cirrhotic patients with a liver stiffness measurement (LSM) <20kPa and a 
platelet count >150000/μL can avoid screening endoscopy [6], the specificity of this strategy for excluding VNT being validated in 
different studies [7]. Furthermore, expanded Baveno VI criteria, obtained by optimizing LSM and platelets (PLT) values (<25kPa and 
>110000/ μL, respectively), have also been proposed and demonstrated to spare a higher proportion of unnecessary EGD when 
compared to Baveno VI criteria [8]. 
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 Both Baveno VI and expanded Baveno VI criteria were proved reliable in large cohorts of patients with compensated cirrhosis 
mostly due to viral and/or alcoholic etiologies, while patients with NAFLD-related cirrhosis are absent or under represented. This is a 
significant limitation considering that in patients with NAFLD-related cirrhosis LSM could also account for severity of steatosis and 
obesity [9,10]. Furthermore, studies assessing the diagnostic accuracy of Baveno VI and expanded Baveno VI criteria considered LSM 
values obtained only by M probe. However, NAFLD patients are at high prevalence of obesity, this issue resulting in frequent need to 
measure LSM by XL probe in case of failure of M probe. 
 We aimed to validate the Baveno VI and expanded Baveno VI criteria in patients with compensated cirrhosis due to NAFLD, 
also taking into account potential differences in LSM values from M and XL probes.  
 
Methods: 
Patients selection:  
Data from 790 patients full filling the above reported inclusion criteria and prospectively recruited at the first diagnosis of NAFLD-
related compensated cirrhosis in 10 different centers were retrospectively reviewed and analyzed.  
Inclusion criteria were presence of a reliable LSM and of an EGD within 6 month of LSM. LSM was obtained by FibroScan machine by 
using M and/or XL probe. In some centers M probe was the only available, in some others both M and XL probes were available. 
When both probes were available some centers used the XL probe only in case of failure of the M probe, some others measured LSM 
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by both probes. Cirrhosis was diagnosed by histology [11] and/or by LSM >11.5 KPa for M probe [12] and >11 KPa for XL probe [13]. 
In patients without histology, diagnosis of NAFLD required detection of ultrasonographic steatosis plus at least one criterion of the 
metabolic syndrome (obesity, diabetes, arterial hypertension, dydlipidemia). Other causes of liver disease were ruled out, including 
alcohol intake >20 g/day during the previous year (evaluated by interview of patients on amount, frequency and type, and confirmed by 
at least one family member), viral (HBsAg, anti-HCV and anti-HIV negativity) and autoimmune hepatitis, hereditary hemochromatosis, 
and alpha1-antitrypsin deficiency. Patients with advanced (Child Pugh B or C) cirrhosis, hepatocellular carcinoma, liver 
transplantation, EV banding, portal or splenic vein thrombosis and splenectomy were excluded. The study cohort finally included 372 
patients from the Centre d’Investigation de la Fibrose Hépatique, Bordeaux University Hospital, 110 patients from the Division of 
Gastroenterology and Hepatology, McGill University Health Centre of Montreal QC, 104 patients for the Section of Gastroenterology 
and Hepatology, University of Palermo, 63 patients from the Hepatology Unit, Ospedale San Giuseppe University of Milan, 36 patients 
from the Division of Gastroenterology, Department of Medical Sciences, University of Torino, 35 patients from the Department of 
Medicine and Therapeutics, The Chinese University of Hong Kong, 25 patients from  the Swiss Liver Center, 21 patients from the 
Department of Pathophysiology and Transplantation, Ca' Granda IRCCS Foundation, Policlinico Hospital,  University of Milan, 12 
patients from the Newcastle Upon Tyne Hospitals NHS Trust, Freeman Hospital, and 12 patients from the Dipartimento di Medicina 
Sperimentale e Clinica, University of Florence.  
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 The study was carried out in accordance with the principles of the Helsinki Declaration, and with local and national laws. 
Approval was obtained from the hospital Internal Review Boards and their Ethics Committees, and written informed consent for the 
study was obtained from all patients. 
 
 
Patients evaluation:  
Clinical and anthropometric data, including BMI, the presence of arterial hypertension and type 2 diabetes, were collected at the time 
of enrollment. The same day a 12-hour overnight fasting blood sample was drawn to determine serum levels of AST, ALT, PLT, 
albumin, total bilirubin, INR, total and HDL cholesterol, triglycerides, and plasma glucose concentration. 
 Transient elastography was performed with the FibroScan (Echosens, Paris, France) medical device, using the M and/or XL 
probes. In each center, LSM was assessed after at least 4 hour fasting, by a trained operator who had previously performed at least 
300 determinations in patients with chronic liver disease. Only patients with 10 valid measurements and with reliable results according 
to published criteria were enrolled [14].  
 EGD was performed by a small number of experienced operators at each Hospital. Patients were excluded from this study, if 
there was more than six month time interval between TE and EGD examinations. At endoscopy, high-risk EV which warrant primary 
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prophylaxis against EV bleeding were defined by medium or large size or the presence of high-risk stigmata findings (red wale marks, 
cherry red spots) [6]. 
 
Statistical analysis  
Continuous variables were summarized as mean ± SD, and categorical variables as frequency and percentage.  
 The training set was defined as the subcohort of patients for which LSM were available by both M and XL  probes, while the 
remaining patients with only one of M or XL probes acted as validation sets. Patients in the training set were used to find two different 
combined thresholds of LSM and Platelets count, one for the M and the other for the XL probe, which maximized the absolute number 
of spared endoscopies while keeping the risk of missed VNTs below 5%. (while constraining the negative predictive value to be at 
least 0.95).  The 5% false negative rate of undetected VNT was agreed as a reasonable criterion by experts in the Baveno VI 
consensus conference and later adopted by the American Gastroenterological Association and several other authors [6]. Found 
thresholds’ performances were subsequently evaluated in their respective validation sets.  
 Baveno VI (LSM <20 KPa and PLT > 150,000) and expanded Baveno VI (LSM <25 KPa and PLT > 110,000) criteria were also 
evaluated in both training and validation sets.  
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 Performance evaluations were made in terms of number and percentage of spared endoscopies, number and percentage of 
undetected EV, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive and negative likelihood 
ratios.  
All the analyses were performed using the R statistical computing environment.  
 
 
 
RESULTS 
Patient characteristics   
The baseline characteristics of the 790 patients with NAFLD-related compensated cirrhosis (682 Child Pugh A5, and 108 Child 
Pugh A6) included in the study are shown in Table 1. Mean age was 62.3 years, with a 55% prevalence of males. Sixty-two percent of 
patients were obese, and diabetes and arterial hypertension were present in 62.8% and 61.1% of cases respectively. Supplemental 
Table 1 shows the characteristics of the population split for each centre. Other 56 patients with NAFLD-related compensated cirrhosis 
were not included in the study because LSM was not reliable [14]. This cohort, compared to the enrolled 790 patients, had similar age 
(61±12 years) and similar prevalence of male gender (60.7%), and of VNT (10.7%), while higher BMI (35.1±8.0 Kg/m2), this last being 
the main cause of LSM unreliability. 
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Liver cirrhosis was diagnosed by histology in 34.4% of patients. EV were present in 31.5% of cases, and VNT in 11.5%. The 
prevalence of EV (55.5% vs 27.4%, p<0.001) and of VNT (29.6% vs 8.6%, p<0.001) was higher in Child Pugh A6 compared to A5 
patients. LSM was similar in patients with histological diagnosis of cirrhosis compared to those without, for both M (24.3±16.5 vs 
25.3±15.8, p=0.44) and XL (22.9±14.0 vs 22.2±15.9, p=0.68) probes. Among the 139 patients with LSM <13 KPa –at lower risk of liver 
damage- the diagnosis of cirrhosis was made by histology in 53.2%, and based on LSM values [12,13] in the remaining 65 patients.  
Three-hundred fourteen patients had LSM by both M and XL probes, and this cohort was considered as the training set. In this 
cohort, LSM by M probe was significantly higher than that by XL probe (24.2±14.7 vs 19.8±14.2; p<0.001). Three-hundred thirty-eight 
and 138 patients had LSM by only M and XL probe, respectively, and these cohorts were considered as validation sets. When 
considering patients with LSM by M probe, those in the training cohort had similar LSM (24.2±14.7 KPa vs 25.6±17.2, p=0.26) and 
PLT (176.5±80.0 103/mmc vs 178.4±98.1, p=0.78) values and similar prevalence of VNT (10.2% vs 13.3%, p=0.21) compared to those 
in the validation cohort, while having a significantly higher prevalence of obesity (64.7% vs 49.8%, p<0.001) and a significantly lower 
prevalence of any grade EV (26.4% vs 36.3%, p=0.006) (Table 1). When looking at patients with LSM by XL probe, those in the 
training cohort had similar PLT values (176.5±80.0 103/mmc vs 176.3±81.6, p=0.98) and similar prevalence of both any grade EV 
(26.4% vs 29.7%, p=0.47) and VNT (10.2% vs 10.1%, p=0.98)  compared to those in the validation cohort, while having a significantly 
lower prevalence of obesity (64.7% vs 88.5%, p<0.001) and significantly lower LSM values (19.8±14.2 KPa vs 27.7±16.9, p<0.001)  
(Table 1). 
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Diagnostic accuracy of LSM and PLT for VNT 
Training Set 
 One hundred six out of 314 patients (33.8%) met Baveno VI criteria as a rule-out for VNT of whom 11 (10.4%) had any grade 
EV and 1 patient (0.9%) had VNT (Table 2A). When looking at expanded Baveno VI criteria 182 out of 314 patients (58%) met criteria 
of whom 30 (16.5%) had any grade EV and 7 patient (3.8%) had VNT (Table 2A).  Consistently, NPV for VNT was 99.1% and 96.2% 
for Baveno VI and expanded Baveno VI criteria, respectively (Table 2A). 
 Furthermore, we tested for new criteria specific for NAFLD-related cirrhosis –hereinafter called NAFLD cirrhosis criteria- and 
discriminated for M or XL probe. We identified as the best thresholds for rule-out VNT, PLT>110,000 and LSM<30 KPa for M probe, 
and PLT>110,000 and LSM<25 KPa for XL probe. The use of these thresholds allowed sparing 68.5% and 65% of EGD, by missing 
4.2% and 4.9% of VNT, and 17.7% and 18.1% of any grade EV, respectively (Table 2A and B). Negative predictive value for VNT was 
95.8% and 95.1% for patients with LSM by M or XL probe, respectively (Table 2A and B). Consistent with these data, usage of NAFLD 
cirrhosis criteria in this cohort would have led 31.5% of patients to EGD screening (99 out of 314), which respectively represents 
34.7% less EGDs than those required using Baveno VI criteria (208 out of 314), and 10.5% less EGDs required using  expanded 
Baveno VI criteria (132 out of 314). 
Validation Set 
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The diagnostic accuracy of Baveno VI, expanded Baveno VI and new NAFLD cirrhosis criteria was tested in the validation cohorts. 
 In the validation cohort of 338 patients with LSM by only M probe, PLT>110,000 and LSM<30 KPa were confirmed better than 
Baveno VI and expanded Baveno VI criteria in terms of spared endoscopy (61.8% VS. 33.4% vs 54.1%) while keeping a similar rate of 
missed VNT (4.8% vs. 4.4% vs 4.4%) and of missed any grade EV (22.5% vs. 18.6% vs 21.3%), and a similar NPV (95.2%, 95.6% 
and 95.6%) (Table 2A). Consistently, the number of needed EGDs with NAFLD cirrhosis criteria is respectively 28.4% and 7.7 % less 
than those needed using BAVENO VI and expanded BAVENO VI criteria.  
 Finally, in the validation cohort of 138 patients with LSM by only XL probe – those where in clinical practice XL probe would be 
used because of failure of M probe- we confirmed the good diagnostic accuracy of PLT>110,000 and LSM<25 KPa in terms of spared 
endoscopy (46.4%), missed VNT (1.6%), missed any grade EV (17.2%), and NPV (98.4%) (Table 2B). 
Sensitivity analyses 
 Sensitivity analyses performed in each center considered separately, confirmed that when considering LSM by M probe the new 
elaborated NAFLD-cirrhosis criteria spared more EGD than Baveno VI and extendend Baveno VI criteria (range 50%-80.6% vs 25%-
52.8% vs  41.7%-60%), while keeping a similar rate of missed VNT (range 0%-8.7% vs 0%-12.5% vs 0%-10%) and any grade EV 
(0%-38.6% vs 0%-32.4% vs 0%-41.3%) (Supplemental Table 2). Similar results were observed when considering the new elaborated 
NAFLD-cirrhosis criteria by using XL probe (range 33.3%-70.3% for spared EGD; 0%-22.2% for missed VNT; 0%-66.7% for missed 
any grade EV) (Supplemental Table 2). 
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 When considering the entire cohort of 652 patients with LSM by M probe – those where in clinical practice M probe would be 
used - Baveno VI, expanded Baveno VI and NAFLD cirrhosis criteria spared 33.6%, 56% and 65% of unnecessary EGD, respectively, 
by missing 2.7%, 4.1% and 4.5% of VNT, respectively.  
 When excluding the 139 patients with LSM<13 kPa –at lower risk of liver disease severity-, the prevalence of any grade EV and 
of VNT was 35.6% and 14.1%, respectively; 412 patients had LSM by M and 344 by XL probe. In these patients NAFLD cirrhosis 
criteria spared 52.2% of unnecessary EGD by using M probe and 50.6% by using XL probe, also showing a good similar rate of 
missed VNT (5.6% and 4.6%, respectively) and missed any grade EV (23.3% and 20.1%, respectively). Notably, in the subgroup of 
patients with LSM by M probe, NAFLD cirrhosis criteria worked better than Baveno VI (18.7% spared EGD, 2.6% missed VNT and 
14.3% missed any grade EV) and expanded Baveno VI (39.6% spared EGD, 4.9% missed VNT and 21.5% missed any grade EV) 
criteria.  
 Finally, when splitting the entire population according to obesity, 110 nonobese and 202 obese patients had LSM by both M and 
XL probe. In the obese group, NAFLD cirrhosis criteria spared 73.8% of unnecessary EGD by using M probe and 70.8% by using XL 
probe, also showing a good similar rate of missed VNT (1.3% and 2.8%, respectively) and missed any grade EV (15.4% for both) 
(Table 3). Notably, when looking at the group of nonobese patients, while NAFLD cirrhosis criteria by M or XL probes showed a similar 
performance, their accuracy was worse than that observed in obese patients. Specifically, in nonobese patients, NAFLD cirrhosis 
criteria spared 59.1% of unnecessary EGD by using M probe and 54.5% by using XL probe, providing a rate of missed VNT of 10.8% 
and 10.5%, respectively, and missed any grade EV of 23.1% and 25%, respectively (Table 3). To strength the robustness of these 
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results, we analyzed separately patients with clinical or histological diagnosis of NAFLD cirrhosis. Notably the worse performance of 
NAFLD cirrhosis criteria was confirmed in both groups. Specifically, in nonobese patients with histological (n=34) or clinical (n=76) 
diagnosis of NAFLD cirrhosis  the rate of missed VNT was 10.5 and 11.1% for the M probe, and 5.5% and 11.9% for the XL probe, 
respectively. 
Similar results by splitting patients according to obesity were observed for both M and XL probe-based NAFLD cirrhosis criteria 
in the entire cohorts of patients with LSM by M or XL probes (data not showed).  
 The different accuracy of NAFLD cirrhosis criteria according to obesity was also confirmed for Baveno VI and expanded 
Baveno VI criteria, even if Baveno VI criteria kept a rate of missed VNT <5% sparing only 20% of EGD (Table 3). Again, these results 
were confirmed in the entire cohorts of patients with LSM by M or XL probes, and in nonobese patients split for clinical or histological 
diagnosis of NAFLD cirrhosis (data not showed).  
 
Characteristics of patients with missed VNT or any grade EV 
 In the entire cohort of 652 patients with LSM by M probe, NAFLD cirrhosis criteria missed 66 patients (15.5%) with small EV 
and 19 patients (4.4%) with VNT. Notably, when considering patients full filling NAFLD cirrhosis criteria, those with missed VNT, when 
compared to those without EV had significantly lower prevalence of obesity (26% vs 61%, p=0.007), and significantly lower PLT 
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(174±71 vs 213±82, p=0.03) and higher LSM (20±5.7 vs 16.9 vs 5.6, p=0.02) values (Table 4A). Similar results were observed for 
patients with missed small EV who had significantly lower PLT (182±68 vs 213±82, p=0.003) and higher LSM (18.5±5.8 vs 16.9±5.6, 
p=0.04) values compared to patients without EV (Table 4A). 
 When looking at the 452 patients with LSM by XL probe, NAFLD cirrhosis criteria missed 37 patients (13.8%) with small EV and 
11 patients (4.1%) with VNT. Notably, among patients fulfilling NAFLD cirrhosis criteria, those with missed VNT when compared to 
those without EV had significantly lower prevalence of obesity (46% vs 78%, p=0.03), and significantly lower PLT (146±27 vs 217±77, 
p=0.002) and higher LSM (16.4±6.4 vs 13.7±5.0, p=0.08) values (Tables 4B). Similar results were observed for patients with missed 
small EV who had significantly lower PLT (186±63 vs 217±77, p=0.02) and a trend for higher LSM (15.2±5.6 vs 13.7±5.0, p=0.09) 
values compared to those without EV (Table 4B). 
 
Discussion 
In this study on a large multicenter cohort of patients with NAFLD-related compensated cirrhosis we confirmed that expanded Baveno 
VI works better than Baveno VI criteria for ruling-out the presence of VNT, sparing more EGD even if slightly increasing the number of 
missed VNT. We also elaborated new more accurate criteria, optimized for M and XL FibroScan probes and always based on LSM 
and PLT values, that were able to spare more than 50% of unnecessary EGD. 
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 Portal hypertension significantly affects the natural history of liver cirrhosis of any etiology, including NAFLD [4]. Along this line, 
the identification of EV by EGD or non-invasive tools is a key clinical need. Baveno VI expert recommendations suggest to avoid EGD 
screening for VNT in patients with LSM<20 KPa and PLT >150,000 mmc [6], and expanded Baveno VI criteria have been also 
suggested [8]. 
 In the present study, we found that Baveno VI and expanded Baveno VI criteria spared 33.8% and 58% of unnecessary EGD by 
missing 0.9% and 3.8% of VNT, respectively, these data being replicated in the validation cohort. Our study firstly validated Baveno VI 
and expanded Baveno VI criteria in the clinical setting of NAFLD-related cirrhosis, overall confirming that the updated criteria work 
better than the original Baveno VI, even if slightly increasing the number of missed VNT. Notably, our data demonstrated a rate of 
spared EGD for Baveno VI criteria higher than the overall 20% reported in patients with cirrhosis due to viral and/or alcohol etiologies 
[7], also showing a higher rate of spared EGD for NAFLD by using the expanded Baveno VI criteria [8]. These data confirmed the 
similar trend observed by Augustin and colleagues in a small cohort of 90 patients with NAFLD-related advanced chronic liver disease 
[8]. This issue could be explained by the impact of viral infections and alcohol use on fluctuation of PLT values, and on hepatic 
inflammation.  
 Baveno VI and expanded Baveno VI criteria were proposed and extensively validated in patients with cirrhosis mostly due to 
viral infections and/or alcohol abuse, and by considering LSM values obtained only by using the M probe. For these reasons, we 
tested for new criteria directly elaborated in NAFLD-related cirrhosis and differentiated for M and XL probes. Notably, while keeping 
110,000 as the best threshold for PLT, we identified in 30 KPa for M probe and 25 KPa for XL probe (the same threshold of LSM 
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applied in the expanded Baveno VI criteria for M probe) the best LSM thresholds, finally generating the new NAFLD cirrhosis criteria. 
When considering the use of M probe, the NAFLD cirrhosis criteria performed better than Baveno VI and expanded Baveno VI 
allowing to spare 68.5% of unnecessary EGD while keeping a similar rate of missed VNT, and replicating these results in the 
validation cohort. The better accuracy of a higher threshold of LSM compared to that of the expanded Baveno VI could be related to 
the fact that the LSM in NAFLD patients is directly related not only to fibrosis and –probably- portal hypertension but also to severity of 
steatosis [9], obesity [10] and higher skin-to-capsule length [15], all factors frequently observed in NAFLD patients. Furthermore, 
NAFLD cirrhosis criteria with modified LSM threshold for XL probe showed a similar good diagnostic accuracy for ruling out patients 
with VNT. These criteria used a lower LSM stiffness value compared to that identified by using the M probe. This is not surprising, 
because, as observed for fibrosis [13], also in a setting of cirrhotic patients, LSM values from XL probe were significantly lower than 
those obtained by using the standard M probe. Notably, the good and better –with respect to Baveno and Baveno VI- accuracy of 
NAFLD cirrhosis criteria for avoiding unnecessary EGD while keeping an acceptable rate of missed VNT, was largely validated in the 
at higher risk cohort of patients with LSM≥13 kPa and in all participating cohorts considered separately, some of these analyses being 
however limited by the small sample size.  
 In the present study we found a higher prevalence of VNT in nonobese compared to obese patients. This data, even if all 
included patients had compensated Child A cirrhosis, could suggest that nononbese patients, as expression of sarcopenia, had a 
more advanced disease – more severe portal hypertension, lower liver function, etc – unfortunately not measurable by Child 
Classification. Notably, from a diagnostic point of view, when splitting the population according to obesity, we confirmed that both M 
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and XL probe-based NAFLD cirrhosis criteria had a similar diagnostic accuracy in obese and nonobese patients. However, we also 
observed that these criteria –as also reported for expanded Baveno VI- had a worse performance in nonobese patients where the rate 
of missed VNT was of about 10%. This picture was further confirmed by the evidence that BMI was significantly lower in patients with 
missed VNT compared those without EV and full filling NAFLD cirrhosis criteria. Differences in skin-to-capsule distance and/or 
steatosis severity between obese and nonobese patients could explain discrepancies in the observed diagnostic performances. From 
a clinical point of view, these data, even if worthy of further validation, suggest to careful interpret non-invasive scores for ruling out 
VNT in nonobese NAFLD patients with cirrhosis, where Baveno VI criteria seems to be more conservative even if sparing only 20% of 
EGD. Anyway, the lack of a fully understanding of this phenomena suggests caution in the interpretation of this result. 
 Another issue from the present study is that by applying Baveno VI, expanded Baveno VI and NAFLD cirrhosis criteria, 
designed to rule-out VNT, we missed about 10%-15% of patients with EV not needing of treatment. This data is clinically relevant 
because the presence of EV significantly affect the prognosis of cirrhotic patients via a higher risk of liver decompensation and death 
[4,5]. Notably, when looking at M or XL probe-based NAFLD cirrhosis criteria, patients with missed EV not needing of treatment had 
significantly higher LSM and lower PLT values compared to patients without EV and considered not worthy of EGD. These data 
potentially suggest that some of these patients when retested at one year, as suggested by Baveno VI recommendations, could transit 
in the area of patients considered worthy of EGD screening.   
 This study has some limitations. First, the analysis of the data was retrospective and the evaluation of EV size has been 
performed by several endoscopists, not testing interobserver agreement. In addition lack of data about gastric varices and portal 
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hypertensive gastropathy could further affect the interpretation of our results. However, the same issues was present in other 
multicenter large studies assessing non-invasive prediction of VNT in cirrhosis [8], and both prevalence of VNT and performance of 
tested scores was similar among centers. Second, interobserver concordance of LSM examinations was also not assessed, this issue 
potentially affecting the interpretation of our results. However, all tests were performed by expert operators following the same protocol 
and fulfilling validity criteria. Moreover, different relevant studies assessing FibroScan in NAFLD were based on multicenter cohorts 
and/or on multiple operators [12,13] .Finally, many different studies reported good interobserver concordance for LSM and CAP 
[16,17]. Another limitation of our study lies in the fact that we cannot rule-out that some patients with reliable LSM by M probe could 
have a skin-to-capsule distance >2.5 cm, this issue potentially affecting the accuracy of our results. The maximum 6 month interval 
between LSM and EGD could further bias our results. A strength of our paper is the availability of both M and XL FibroScan probes in 
a large population of NAFLD patients. Next generation FibroScan devices directly drive the use of M and XL probe and devices under 
development will adjust LSM values eliminating differences related to probes. However available devices will be still used for many 
years so we are confident that our study adds relevant insights in this topic. A further methodological issue is the potentially limited 
external validity of the results for different populations and settings. Our study included a cohort of NAFLD-related compensated 
cirrhotic subjects, largely obese, who were referred to tertiary centers for liver disease, limiting the applicability of the results in 
different populations, and especially in Asiatic populations largely under-represented in this study. Finally, lack of follow-up data may 
limit the potency of our results. 
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 In conclusion, we demonstrated that, in a large cohort of patients with compensated cirrhosis due to NAFLD, the new 
elaborated NAFLD cirrhosis criteria differentiated for FibroScan probe, can safely spare more than 50% of unnecessary EGD, working 
better than the already proposed Baveno VI and expanded Baveno VI criteria. Prospective studies are needed to further validate our 
results. 
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Table 1. Baseline Demographic, Metabolic, Laboratory and Instrumental Features of patients with NAFLD-related cirrhosis.  
 
 NAFLD Cirrhosis 
Entire Cohort 
N=790 
NAFLD Cirrhosis 
Training Cohort 
N=314 
NAFLD Cirrhosis 
Validation Cohort M Probe 
N=338 
NAFLD Cirrhosis 
Validation Cohort XL Probe 
N=138 
 
P value° 
 
P valueç 
Mean Age – years 62 ± 10 63 ± 11 62 ± 10 2 ± 11 0.593 0.406 
Male Gender 55 % 60 % 
 
55 % 44 % 0.239 0.001 
Mean BMI – Kg/m2 32.6 ± 6.7 33.3 ± 6.7 30.3±5.0 37.5 ± 7.6 <0.001 <0.001 
ALT – IU/L 55 ± 42 54 ± 41 59 ± 44 46 ± 36 0.104 0.070 
PLT – 103/mmc 177 ± 85 177 ± 80 178 ± 90 176 ± 82 0.785 0.980 
Total Bilirubin – mg/dL 1.0±0.5 1.0±0.4 1.0±0.5 1.0±0.6 0.981 0.942 
INR 1.0±0.2 1.0±0.4 1.0±0.2 1.0±0.2 0.954 0.896 
Albumin – g/L 4.1 ± 0.5 4.1 ± 0.4 4.2 ± 0.5 3.9 ± 0.6 0.312 <0.001 
Blood Glucose – mg/dL 129 ± 54 133 ± 61 125 ± 48 127 ± 47 0.126 0.430 
Total Cholesterol – mg/dL 178 ± 49 183 ± 46 178 ± 51 164 ± 48 0.186 <0.001 
Triglycerides – mg/dL 161± 123 183 ± 127 141 ± 120 162 ± 109 <0.001 0.136 
Type 2 Diabetes 62.8 % 64.9% 62.0 % 59.8% 0.480 0.352 
Arterial Hypertension 61.2% 60.8 % 63.2% 56.7% 0.558 0.480 
LSM by M probe– Kpa* 
LSM by XL probe- KPa# 
25 ± 16 
22 ± 16 
24 ± 15 
20 ± 14 
26 ± 17 
- 
- 
28 ± 17 
0.264 
- 
- 
<0.001 
Esophageal Varices 
Presence 
VNT 
 
31.3 % 
11.5 % 
 
26.4 % 
10.2 % 
 
36.4 % 
13.3 % 
 
29.7 % 
10.1 % 
 
0.008 
0.266 
 
0.545 
1.000 
 
Abbreviations: BMI, body mass index; PLT, platelet; ALT, alaninoaminotransferase; LSM, liver stiffness measurement; VNT, Varices needed of treatment. Data are given as 
mean ± standard deviation, or as percentage of cases (%). 
*Data relative to 652 patients; #Data relative to 452 patients; ° comparison between Training Cohort and Validation Cohort M Probe; ç comparison between Training 
Cohort and Validation Cohort XL Probe. 
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Table 2. Diagnostic Accuracy for VNT of Baveno VI, Extended Baveno VI and NAFLD Cirrhosis Criteria in Training and Validation Sets of Patients with NAFLD-
related Compensated Cirrhosis. 
 
A 
Training Set 
M Probe 
N = 314 
Validation Set 
M Probe 
N = 338 
B  
Training Set 
XL Probe 
N = 314 
Validation Set 
XL Probe 
N = 138 
VNT (%)→ 32 (10) 45 (13)  VNT (%)→ 32 (10) 14 (10) 
Baveno VI Criteria  
PLT> 150 X103 and LSM < 20 KPa 
Spared Endoscopies (%) 
Missed VNT n. (%) 
Missed EV (%) 
sensitivity  
specificity  
Negative Predictive Value 
Positive Predictive Value 
Positive Likelihood Ratio 
Negative Likelihood Ratio 
106(33.8) 
1(0.9) 
11(10.4) 
0.97 
0.37 
0.99 
0.15 
1.54 
0.08 
113(33.4) 
5(4.4) 
21(18.6) 
0.89 
0.37 
0.96 
0.18 
1.41 
0.30 
  - - 
Extended Baveno VI Criteria 
PLT> 110 X103 and LSM < 25 KPa 
Spared Endoscopies (%) 
Missed VNT n. (%) 
Missed EV (%) 
sensitivity  
specificity  
Negative Predictive Value 
Positive Predictive Value 
Positive Likelihood Ratio 
Negative Likelihood Ratio 
182(58) 
7(3.8) 
30(16.5) 
0.78 
0.62 
0.96 
0.19 
2.06 
0.35 
183(54.1) 
8(4.4) 
39(21.3) 
0.82 
0.60 
0.96 
0.24 
2.04 
0.30 
   
 
 
 
 
- 
 
 
 
 
 
- 
NAFLD Cirrhosis Criteria 
PLT> 110 X103 and LSM < 30 KPa 
Spared Endoscopies (%) 
Missed VNT n. (%) 
Missed EV (%) 
sensitivity  
specificity  
Negative Predictive Value 
Positive Predictive Value 
Positive Likelihood Ratio 
Negative Likelihood Ratio 
215(68.5) 
9(4.2) 
38(1 
7.7) 
0.72 
0.73 
0.96 
0.23 
2.67 
0.39 
209(61.8) 
10(4.8) 
47(22.5) 
0.78 
0.68 
0.95 
0.27 
2.42 
0.33 
 
 
 
NAFLD  Cirrhosis Criteria 
PLT> 110 X103 and LSM < 25 KPa 
 204(65) 
10(4.9) 
37(18.1) 
0.69 
0.69 
0.95 
0.20 
2.20 
0.45 
64(46.4) 
1(1.6) 
11(17.2) 
0.93 
0.51 
0.98 
0.18 
1.89 
0.14 
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Table 3. Diagnostic Accuracy for VNT of Baveno VI, Extended Baveno VI and NAFLD Cirrhosis Criteria in Obese and Nonobese Patients with NAFLD-related 
Compensated Cirrhosis and with LSM by both M and XL Probes. 
 
A 
BMI >= 30 
M Probe 
N = 202 
BMI < 30 
M Probe 
N = 110 
B  
BMI >= 30 
XL Probe 
N = 202 
BMI < 30 
XL Probe 
N = 110 
EVNT (%)→ 12 (6) 19 (17)  VNT (%)→ 12 (6) 19 (17) 
NAFLD Cirrhosis Criteria 
PLT> 110 X103 and LSM < 30 KPa 
Spared Endoscopies (%) 
Missed VNT n. (%) 
Missed EV (%) 
sensitivity  
specificity  
Negative Predictive Value 
Positive Predictive Value 
Positive Likelihood Ratio 
Negative Likelihood Ratio 
149(73.8) 
2(1.3) 
23(15.4) 
0.83 
0.77 
0.99 
0.19 
3.68 
0.22 
65(59.1) 
7(10.8) 
15(23.1) 
0.63 
0.64 
0.89 
0.27 
1.74 
0.58 
NAFLD Cirrhosis Criteria 
PLT> 110 X103 and LSM < 25 KPa  
143(70.8) 
4(2.8) 
22(15.4) 
0.67 
0.73 
0.97 
0.14 
2.49 
0.46 
60(54.5) 
6(10) 
15(25) 
0.68 
0.59 
0.90 
0.26 
1.68 
0.53 
Baveno VI Criteria  
PLT> 150 X103 and LSM < 20 KPa 
Spared Endoscopies (%) 
Missed VNT n. (%) 
Missed EV (%) 
sensitivity  
specificity  
Negative Predictive Value 
Positive Predictive Value 
Positive Likelihood Ratio 
Negative Likelihood Ratio 
82(40.6) 
0 
7(8.5) 
1 
0.43 
1 
0.1 
1.76 
0 
23(20.9) 
1(4.3) 
4(17.4) 
0.95 
0.24 
0.96 
0.21 
1.25 
0.22 
   
 
 
 
- 
 
 
 
 
- 
Extended Baveno VI Criteria 
PLT> 110 X103 and LSM < 25 KPa 
Spared Endoscopies (%) 
Missed VNT n. (%) 
Missed EV (%) 
sensitivity  
specificity  
Negative Predictive Value 
Positive Predictive Value 
Positive Likelihood Ratio 
Negative Likelihood Ratio 
127(62.9) 
0 
16(12.6) 
1 
0.67 
1 
0.16 
3.02 
0 
54(49.1) 
7(13) 
14(25.9) 
0.63 
0.52 
0.87 
0.21 
1.31 
0.71 
   
 
 
 
- 
 
 
 
 
- 
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Table 4. Differences in Baseline Demographic, Metabolic, Laboratory and Instrumental Features of patients with NAFLD-related cirrhosis full filling NAFLD 
Cirrhosis Criteria and split according to absence of EV or presence of Small EV or VNT. 
 
(A) NAFLD Cirrhosis Criteria by M Probe 
 Small EV VNT No EV P value*  P value° 
     N=66     N=19    N=339   
Male Gender (%)     42 (64)      13 (68)     178 (53)   0.12  0.26 
Age - years  64.3±9.8  66.5±9.1  60.8±10.8  0.01  0.02 
PLT – 103/mmc 182±68 174±71 213±82  0.003  0.03 
BMI – Kg/m2  32.8±6.3  27.9±3.9  32.5±6.5  0.79  0.002 
BMI≥30 Khìg/m2 (%)     41 (66)       5 (26)     194 (61)   0.50  0.007 
LSM - KPa  18.5±5.8  20.0±5.7  16.9±5.6  0.04  0.02 
ALT - IU 60±47  57±33 61±47 0.83 0.72 
 
 
(B) NAFLD Cirrhosis Criteria by XL Probe 
 
 Small EV VNT No EV P value*  P value* 
     N=37    N=11    N=220   
Male Gender (%)     26 (70)       8 (73)     120 (55)   0.10  0.38 
Age - years  63.3±9.2  66.6±11.3  60.1±11.4  0.10  0.06 
PLT – 103/mmc 186±63 146±27 217±77  0.02  0.002 
BMI – Kg/m2  33.6±6.4  30.0±4.6  35.8±7.4  0.09  0.01 
BMI≥30 Khìg/m2 (%)     23 (66)       5 (46)     159 (78)   0.19  0.03 
LSM - KPa  15.2±5.6  16.4±6.4  13.7±5.0  0.09  0.08 
ALT - IU  57±48  50±32  57±46  0.99  0.62 
 
*Comparison between patients with small EV and those without EV; °Comparison between patients with VNT and those without EV. 
 
